Hims & Hers stock just fell 16.5% to about US$19 in regular trading, wiping out a chunk of short term gains after Q3 2026 results hit the tape. The selloff lands on a quarter where revenue reached US$890.4m and the business generated US$82m of adjusted earnings before interest, tax, depreciation and amortisation, even as it still reported a US$33m loss. Traders are reacting to the profit squeeze and guidance reset. Longer term investors are now weighing a fast growing digital health platform with rising cash generation against a valuation that already bakes in ambitious multi year expectations.

Love the top line momentum at Hims & Hers Health, but uneasy about a quarter that still ends in a US$33m loss and a guidance reset. This…